Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on Enzalutamide PK in Healthy Men
NCT02138799Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Area under the curve from time 0 to 336 hours and Area under the curve extrapolated to infinity. Started Jul 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02138799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138799.